Carbimazole, Thiamazole (Methimazole)

Table   Graphic     exposition period:

Congenital malformations
Adverse outcome OR 95%CII2k No. casesNo. exposedpublication biasROBE-value
All congenital malformations (majors, minors, majors and minors, or unspecified)1.40 [1.14, 1.72]26%13 studies249,1324,773low ROB2.15 [1.54; .]
Major congenital malformations1.78 [1.18, 2.69]8%7 studies2051,852serious ROB2.95 [1.63; .]
Genital anomalies1.11 [0.75, 1.63]0%3 studies25,7662,856not evaluable ROB-
Limb defects0.85 [0.65, 1.12]0%3 studies74,5332,856not evaluable ROB-
Respiratory system anomalies1.62 [1.11, 2.37]0%3 studies15,9982,856not evaluable ROB2.63 [1.46; .]
Urinary malformations1.69 [1.08, 2.67]0%3 studies17,6452,856not evaluable ROB2.78 [1.37; .]
Carbimazole embryopathy14.62 [10.40, 20.55]0%6 studies2,3164,301not evaluable ROB28.73 [20.29; .]
Eye defects2.38 [1.21, 4.71]0%2 studies2,4931,736not evaluable ROB4.20 [1.70; .]
Congenital heart defects1.73 [1.40, 2.15]0%3 studies77,4052,856not evaluable ROB2.86 [2.14; .]
Digestive system anomalies2.99 [2.05, 4.36]0%3 studies15,2732,856not evaluable ROB5.43 [3.52; .]
Severe congenital heart defect0.87 [0.25, 3.03]0%2 studies7391,311not evaluable ROB-
Abdominal wall defects5.44 [2.63, 11.23]0%2 studies9331,736not evaluable ROB10.35 [4.70; .]
Ear, face and neck anomalies0.58 [0.08, 4.33]0%2 studies9121,736not evaluable ROB-
Nervous system anomalies2.85 [1.39, 5.87]0%2 studies5,8521,282not evaluable ROB5.15 [2.12; .]
Omphalocele9.70 [3.27, 28.78]0%3 studies1631,334not evaluable ROB18.89 [6.00; .]
Syndromes and chromosomal abnormalities1.16 [0.62, 2.17]0%2 studies5,5531,736not evaluable ROB-
Ano-rectal atresia and stenosis1.77 [0.22, 14.34]13%2 studies41,254not evaluable ROB-
Atresia of bile ducts2.94 [0.36, 24.10]0%2 studies31,254not evaluable ROB-
Cardiac septal defects1.87 [1.14, 3.06]-1 study1,097not evaluable ROB3.15 [1.55; .]
Congenital hydronephrosis4.41 [0.48, 40.36]0%2 studies31,254not evaluable ROB-
Hypospadias3.81 [0.32, 46.05]0%2 studies11,254not evaluable ROB-
Oro-facial clefts1.54 [0.19, 12.70]28%2 studies3,4481,143not evaluable ROB-
Other congenital malformations (Q80-84)2.32 [0.38, 14.27]50%2 studies2,0221,736not evaluable ROB-
Ventricular septal defect1.31 [0.56, 3.06]0%2 studies251,254not evaluable ROB-
Situs inversus5.49 [0.58, 51.80]0%2 studies251,311not evaluable ROB-
Aplasia cutis congenita23.36 [1.33, 409.42]-1 study71,231not evaluable ROB46.22 [2.00; .]
Choanal atresia25.89 [7.52, 89.13]0%2 studies11992not evaluable ROB51.28 [14.52; .]
26 non statistically significant endpoints reported in only one study

Growth parameters and prematurity
Adverse outcome OR 95%CII2k No. casesNo. exposedpublication biasROBE-value
Preterm (< 37 weeks)1.21 [0.65, 2.23]0%4 studies184227not evaluable ROB-
Low birth weight (< 2500g)1.60 [0.46, 5.51]25%2 studies14180not evaluable ROB-
1 non statistically significant endpoints reported in only one study

Maternal consequences
Adverse outcome OR 95%CII2k No. casesNo. exposedpublication biasROBE-value
Caesarean--0 study-
3 non statistically significant endpoints reported in only one study

Neonatal disorders
Adverse outcome OR 95%CII2k No. casesNo. exposedpublication biasROBE-value
Goiter0.96 [0.20, 4.60]0%3 studies661not evaluable ROB-
Hearing loss / Auditory deficit3.68 [0.41, 32.73]0%2 studies41,254not evaluable ROB-
Hypothyroidism (fetal/neonatal)0.88 [0.10, 7.50]0%3 studies154not evaluable ROB-
Hyperthyroidism / Thyrotoxicosis (fetal/neonatal)0.77 [0.06, 9.94]0%2 studies118not evaluable ROB-
1 non statistically significant endpoints reported in only one study

Intrauterine deaths
Adverse outcome OR 95%CII2k No. casesNo. exposedpublication biasROBE-value
Elective/induced termination of pregnancy3.39 [1.80, 6.37]0%2 studies461,550not evaluable ROB6.23 [3.00; .]
Perinatal death0.70 [0.25, 1.94]0%2 studies161,550not evaluable ROB-
Early intrauterine death (< 22 weeks)3.94 [0.70, 22.25]93%2 studies3321,654not evaluable ROB-
Intrauterine deaths (as a whole or unspecified)1.97 [0.89, 4.35]0%2 studies26131not evaluable ROB-

Neuro-developmental disorders
Adverse outcome OR 95%CII2k No. casesNo. exposedpublication biasROBE-value
Neuro-developmental disorders (as a whole)5.34 [2.17, 13.10]-1 study69220not evaluable ROB10.15 [3.77; .]
1 non statistically significant endpoints reported in only one study

- About - Master protocol - Browse exposition - RSS - Made with in Lyon - Contact us - Privacy policy - Licence Creative Commons